Effect of diet and weight loss on the severity of psoriasis

[1] Capon F. The genetic basis of psoriasis. Int J Mol Sci. 2017; 18: 2526. CaponF The genetic basis of psoriasis Int J Mol Sci 2017 18 2526 10.3390/ijms18122526575112929186830 Search in Google Scholar

[2] Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol. 2004; 135: 1–8. GudjonssonJE JohnstonA SigmundsdottirH ValdimarssonH Immunopathogenic mechanisms in psoriasis Clin Exp Immunol 2004 135 1 8 10.1111/j.1365-2249.2004.02310.x180892814678257 Search in Google Scholar

[3] Chen L, Tsai TF. HLA-Cw6 and psoriasis. Br J Dermatol. 2018; 178: 854–862. ChenL TsaiTF HLA-Cw6 and psoriasis Br J Dermatol 2018 178 854 862 10.1111/bjd.16514 Search in Google Scholar

[4] Murphy EC, Nussbaum D, Prussick R, Friedman AJ. Use of complementary and alternative medicine by patients with psoriasis. J Am Acad Dermatol. 2019; 81: 280–283. MurphyEC NussbaumD PrussickR FriedmanAJ Use of complementary and alternative medicine by patients with psoriasis J Am Acad Dermatol 2019 81 280 283 10.1016/j.jaad.2019.03.05930935988 Search in Google Scholar

[5] Danielsen K, Olsen AO, Wilsgaard T, Furberg AS. Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort. Br J Dermatol. 2013; 168: 1303–1310. DanielsenK OlsenAO WilsgaardT FurbergAS Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort Br J Dermatol 2013 168 1303 1310 10.1111/bjd.1223023374051 Search in Google Scholar

[6] Kunz M, Simon JC, Saalbach A. Psoriasis: Obesity and fatty acids. Front Immunol. 2019; 10: 1807. KunzM SimonJC SaalbachA Psoriasis: Obesity and fatty acids Front Immunol 2019 10 1807 10.3389/fimmu.2019.01807668494431417571 Search in Google Scholar

[7] Owczarczyk-Saczonek A, Placek W. Compounds of psoriasis with obesity and overweight. Postepy Hig Med Dosw. 2017; 71: 761–772. Owczarczyk-SaczonekA PlacekW Compounds of psoriasis with obesity and overweight Postepy Hig Med Dosw 2017 71 761 772 10.5604/01.3001.0010.385428894050 Search in Google Scholar

[8] Budu-Aggrey A, Brumpton B, Tyrrell J, Watkins S, Modalsli EH, Celis-Morales C, Ferguson LD, Vie GA, Palmer T, Fritsche LG, et al. Evidence of a causal relationship between body mass index and psoriasis: A Mendelian randomization study. PLoS Med. 2019; 16: e1002739. Budu-AggreyA BrumptonB TyrrellJ WatkinsS ModalsliEH Celis-MoralesC FergusonLD VieGA PalmerT FritscheLG Evidence of a causal relationship between body mass index and psoriasis: A Mendelian randomization study PLoS Med 2019 16 e1002739 10.1371/journal.pmed.1002739635495930703100 Search in Google Scholar

[9] Mahil SK, McSweeney SM, Kloczko E, McGowan B, Barker JN, Smith CH. Does weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis? A critically appraised topic. Br J Dermatol. 2019; 181: 946–953. MahilSK McSweeneySM KloczkoE McGowanB BarkerJN SmithCH Does weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis? A critically appraised topic Br J Dermatol 2019 181 946 953 10.1111/bjd.1774130729517 Search in Google Scholar

[10] Jin Y, Zhang F, Yang S, Kong Y, Xiao F, Hou Y, Fan X, Zhang X. Combined effects of HLA-Cw6, body mass index and waist-hip ratio on psoriasis vulgaris in Chinese Han population. J Dermatol Sci. 2008; 52: 123–129. JinY ZhangF YangS KongY XiaoF HouY FanX ZhangX Combined effects of HLA-Cw6, body mass index and waist-hip ratio on psoriasis vulgaris in Chinese Han population J Dermatol Sci 2008 52 123 129 10.1016/j.jdermsci.2008.04.01618585007 Search in Google Scholar

[11] Langan SM, Seminara NM, Shin DB, Troxel AB, Kimmel SE, Mehta NN, Margolis DJ, Gelfand JM. Prevalence of metabolic syndrome in patients with psoriasis: A population-based study in the United Kingdom. J Invest Dermatol. 2012; 132: 556–562. LanganSM SeminaraNM ShinDB TroxelAB KimmelSE MehtaNN MargolisDJ GelfandJM Prevalence of metabolic syndrome in patients with psoriasis: A population-based study in the United Kingdom J Invest Dermatol 2012 132 556 562 10.1038/jid.2011.365327849922113483 Search in Google Scholar

[12] Wong Y, Nakamizo S, Tan KJ, Kabashima K. An update on the role of adipose tissues in psoriasis. Front Immunol. 2019; 10: 1507. WongY NakamizoS TanKJ KabashimaK An update on the role of adipose tissues in psoriasis Front Immunol 2019 10 1507 10.3389/fimmu.2019.01507660987331316526 Search in Google Scholar

[13] Longo M, Zatterale F, Naderi J, Parrillo L, Formisano P, Raciti GA, Beguinot F, Miele C. Adipose tissue dysfunction as determinant of obesity-associated metabolic complications. Int J Mol Sci. 2019; 20: 2358. LongoM ZatteraleF NaderiJ ParrilloL FormisanoP RacitiGA BeguinotF MieleC Adipose tissue dysfunction as determinant of obesity-associated metabolic complications Int J Mol Sci 2019 20 2358 10.3390/ijms20092358653907031085992 Search in Google Scholar

[14] Vega-Robledo GB, Rico-Rosillo MG. Adipose tissue: Immune function and alterations caused by obesity. Rev Alerg Mex. 2019; 66: 340–353. Vega-RobledoGB Rico-RosilloMG Adipose tissue: Immune function and alterations caused by obesity Rev Alerg Mex 2019 66 340 353 Search in Google Scholar

[15] Carrascosa JM, Rocamora V, Fernandez-Torres RM, Jimenez-Puya R, Moreno JC, Coll-Puigserver N, Fonseca E. Obesity and psoriasis: Inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications. Actas Dermo-Sifiliográficas (English Ed.). 2014; 105: 31–44. CarrascosaJM RocamoraV Fernandez-TorresRM Jimenez-PuyaR MorenoJC Coll-PuigserverN FonsecaE Obesity and psoriasis: Inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications Actas Dermo-Sifiliográficas (English Ed.) 2014 105 31 44 10.1016/j.adengl.2012.08.024 Search in Google Scholar

[16] Boehncke WH, Boehncke S, Tobin AM, Kirby B. The “psoriatic march:” A concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011; 20: 303–307. BoehnckeWH BoehnckeS TobinAM KirbyB The “psoriatic march:” A concept of how severe psoriasis may drive cardiovascular comorbidity Exp Dermatol 2011 20 303 307 10.1111/j.1600-0625.2011.01261.x21410760 Search in Google Scholar

[17] Han SJ, Glatman Zaretsky A, Andrade-Oliveira V, Collins N, Dzutsev A, Shaik J, Morais da Fonseca D, Harrison OJ, Tamoutounour S, Byrd AL, et al. White adipose tissue is a reservoir for memory T cells and promotes protective memory responses to infection. Immunity. 2017; 47: 1154–1168. HanSJ Glatman ZaretskyA Andrade-OliveiraV CollinsN DzutsevA ShaikJ Morais da FonsecaD HarrisonOJ TamoutounourS ByrdAL White adipose tissue is a reservoir for memory T cells and promotes protective memory responses to infection Immunity 2017 47 1154 1168 10.1016/j.immuni.2017.11.009577306829221731 Search in Google Scholar

[18] Saczonek A, Krajewska-Włodarczyk M, Kasprowicz-Furmańczyk M, Placek W. Immunological memory of psoriatic lesions. Int J Mol Sci. 2020; 21: 625. SaczonekA Krajewska-WłodarczykM Kasprowicz-FurmańczykM PlacekW Immunological memory of psoriatic lesions Int J Mol Sci 2020 21 625 10.3390/ijms21020625701414831963581 Search in Google Scholar

[19] Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, Cao W, Wang YH, Su B, Nestle FO, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007; 449: 564–569. LandeR GregorioJ FacchinettiV ChatterjeeB WangYH HomeyB CaoW WangYH SuB NestleFO Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide Nature 2007 449 564 569 10.1038/nature0611617873860 Search in Google Scholar

[20] Reinholz M, Ruzicka T, Schauber J. Cathelicidin LL-37: An antimicrobial peptide with a role in inflammatory skin disease. Ann Dermatol. 2012; 24: 126–135. ReinholzM RuzickaT SchauberJ Cathelicidin LL-37: An antimicrobial peptide with a role in inflammatory skin disease Ann Dermatol 2012 24 126 135 10.5021/ad.2012.24.2.126334690122577261 Search in Google Scholar

[21] Naldi L, Addis A, Chimenti S, Giannetti A, Picardo M, Tomino C, Maccarone M, Chatenoud L, Bertuccio P, Caggese E, et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis: Evidence from the Psocare project. Dermatology. 2008; 217: 365–373. NaldiL AddisA ChimentiS GiannettiA PicardoM TominoC MaccaroneM ChatenoudL BertuccioP CaggeseE Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis: Evidence from the Psocare project Dermatology 2008 217 365 373 10.1159/00015659918810241 Search in Google Scholar

[22] Singh S, Facciorusso A, Singh AG, Vande Casteele N, Zarrinpar A, Prokop LJ, Gruvald EL, Curtis JR, Sandborn WJ. Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. PLoS One. 2018; 13: e0195123. SinghS FacciorussoA SinghAG Vande CasteeleN ZarrinparA ProkopLJ GruvaldEL CurtisJR SandbornWJ Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis PLoS One 2018 13 e0195123 10.1371/journal.pone.0195123595739529771924 Search in Google Scholar

[23] Driessen RJB, Boezeman JB, Van De Kerkhof PCM, De Jong EMGJ. Cardiovascular risk factors in high-need psoriasis patients and its implications for biological therapies. Dermatolog Treat. 2009; 20: 42–47. DriessenRJB BoezemanJB Van De KerkhofPCM De JongEMGJ Cardiovascular risk factors in high-need psoriasis patients and its implications for biological therapies Dermatolog Treat 2009 20 42 47 10.1080/0954663080222570218649164 Search in Google Scholar

[24] Hossler EW, Wood GC, Still CD, Mowad CM, Maroon MS. The effect of weight loss surgery on the severity of psoriasis. Br J Dermatol. 2013; 168: 660–661. HosslerEW WoodGC StillCD MowadCM MaroonMS The effect of weight loss surgery on the severity of psoriasis Br J Dermatol 2013 168 660 661 10.1111/j.1365-2133.2012.11211.x489674122880618 Search in Google Scholar

[25] Egeberg A, Sørensen JA, Gislason GH, Knop FK, Skov L. Incidence and prognosis of psoriasis and psoriatic arthritis in patients undergoing bariatric surgery. JAMA Surg. 2017; 152: 344–349. EgebergA SørensenJA GislasonGH KnopFK SkovL Incidence and prognosis of psoriasis and psoriatic arthritis in patients undergoing bariatric surgery JAMA Surg 2017 152 344 349 10.1001/jamasurg.2016.461028002543 Search in Google Scholar

[26] Li W, Han J, Qureshi AA. Obesity and risk of incident psoriatic arthritis in US women. Ann Rheum Dis. 2012; 71: 1267–1272. LiW HanJ QureshiAA Obesity and risk of incident psoriatic arthritis in US women Ann Rheum Dis 2012 71 1267 1272 10.1136/annrheumdis-2011-201273418375422562978 Search in Google Scholar

[27] Eder L, Harvey P, Chandran V, Rosen CF, Dutz J, Elder JT, Rahman P, Ritchlin CT, Rohekar S, Hayday R, et al. Gaps in diagnosis and treatment of cardiovascular risk factors in patients with psoriatic disease: An international multicenter study. J Rheumatol. 2018; 45: 378–384. EderL HarveyP ChandranV RosenCF DutzJ ElderJT RahmanP RitchlinCT RohekarS HaydayR Gaps in diagnosis and treatment of cardiovascular risk factors in patients with psoriatic disease: An international multicenter study J Rheumatol 2018 45 378 384 10.3899/jrheum.170379584584529419462 Search in Google Scholar

[28] Eder L, Thavaneswaran A, Chandran V, Cook RJ, Gladman DD. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis. 2015; 74: 813–817. EderL ThavaneswaranA ChandranV CookRJ GladmanDD Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis Ann Rheum Dis 2015 74 813 817 10.1136/annrheumdis-2013-20444824431392 Search in Google Scholar

[29] Galíndez E, Carmona L. Is obesity in psoriatic arthritis associated with a poorer therapeutic response and more adverse effects of treatment with an anchor drug? Reumatol Clínica (English Ed.). 2016; 12: 307–312. GalíndezE CarmonaL Is obesity in psoriatic arthritis associated with a poorer therapeutic response and more adverse effects of treatment with an anchor drug? Reumatol Clínica (English Ed.) 2016 12 307 312 10.1016/j.reumae.2015.12.002 Search in Google Scholar

[30] Haroon M, Gallagher P, Heffernan E, FitzGerald O. High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease. J Rheumatol. 2014; 41: 1357–1365. HaroonM GallagherP HeffernanE FitzGeraldO High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease J Rheumatol 2014 41 1357 1365 10.3899/jrheum.14002124931949 Search in Google Scholar

[31] Klingberg E, Bilberg A, Björkman S, Hedberg M, Jacobsson L, Forsblad-d’Elia H, Carlsten H, Eliasson B, Larsson I. Weight loss improves disease activity in patients with psoriatic arthritis and obesity: An interventional study. Arthritis Res Ther. 2019; 21: 17. KlingbergE BilbergA BjörkmanS HedbergM JacobssonL Forsblad-d’EliaH CarlstenH EliassonB LarssonI Weight loss improves disease activity in patients with psoriatic arthritis and obesity: An interventional study Arthritis Res Ther 2019 21 17 10.1186/s13075-019-1810-5633046330635024 Search in Google Scholar

[32] Minno MND, Peluso R, Iervolino S, Russolillo A, Lupoli R, Scarpa R. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Ann Rheum Dis. 2014; 73: 1157–1162. MinnoMND PelusoR IervolinoS RussolilloA LupoliR ScarpaR Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers Ann Rheum Dis 2014 73 1157 1162 10.1136/annrheumdis-2012-202812403311423771989 Search in Google Scholar

[33] Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A, IMPACT 2 Trial Investigators. Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial. Ann Rheum Dis. 2005; 64: 1150–1157. AntoniC KruegerGG de VlamK BirbaraC BeutlerA GuzzoC ZhouB DooleyLT KavanaughA IMPACT 2 Trial Investigators Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial Ann Rheum Dis 2005 64 1150 1157 10.1136/ard.2004.032268175560915677701 Search in Google Scholar

[34] Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Salonen D, Rubenstein J, Sharp JT, Tsuji W. Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004; 50: 2264–2272. MeasePJ KivitzAJ BurchFX SiegelEL CohenSB OryP SalonenD RubensteinJ SharpJT TsujiW Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression Arthritis Rheum 2004 50 2264 2272 10.1002/art.2033515248226 Search in Google Scholar

[35] McGonagle DG, Helliwell P, Veale D. Enthesitis in psoriatic disease. Dermatology. 2012; 225: 100–109. McGonagleDG HelliwellP VealeD Enthesitis in psoriatic disease Dermatology 2012 225 100 109 10.1159/00034153623108016 Search in Google Scholar

[36] Kruglikov I, Wollina U. Local effects of adipose tissue in psoriasis and psoriatic arthritis. Psoriasis Targets Ther. 2017; 7: 17–25. KruglikovI WollinaU Local effects of adipose tissue in psoriasis and psoriatic arthritis Psoriasis Targets Ther 2017 7 17 25 10.2147/PTT.S122959577460029387604 Search in Google Scholar

[37] Chiricozzi A, Gisondi P, Girolomoni G. The pharmacological management of patients with comorbid psoriasis and obesity. Expert Opin Pharmacother. 2019; 20: 863–872. ChiricozziA GisondiP GirolomoniG The pharmacological management of patients with comorbid psoriasis and obesity Expert Opin Pharmacother 2019 20 863 872 10.1080/14656566.2019.158320730794469 Search in Google Scholar

[38] Gisondi P, Bellinato F, Conti A, Dapavo P, Piaserico S, De Simone C, Chiricozzi A, Dattola A, Malagoli P, Malara G, et al. Consensus on the place in therapy of TNF-α inhibitors in the treatment of patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2020; 34: e470–e472. GisondiP BellinatoF ContiA DapavoP PiasericoS De SimoneC ChiricozziA DattolaA MalagoliP MalaraG Consensus on the place in therapy of TNF-α inhibitors in the treatment of patients with chronic plaque psoriasis J Eur Acad Dermatol Venereol 2020 34 e470 e472 10.1111/jdv.1638032189348 Search in Google Scholar

[39] Hugh J, Van Voorhees AS, Nijhawan RI, Bagel J, Lebwohl M, Blauvelt A, Hsu S, Weinberg JM. From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. J Am Acad Dermatol. 2014; 70: 168–177. HughJ Van VoorheesAS NijhawanRI BagelJ LebwohlM BlauveltA HsuS WeinbergJM From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies J Am Acad Dermatol 2014 70 168 177 10.1016/j.jaad.2013.09.02024184141 Search in Google Scholar

[40] Maza A, Montaudié H, Sbidian E, Gallini A, Aractingi S, Aubin F, Bachelez H, Cribier B, Joly P, Jullien D, et al. Oral cyclosporin in psoriasis: A systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. J Eur Acad Dermatol Venereol. 2011; 25: 19–27. MazaA MontaudiéH SbidianE GalliniA AractingiS AubinF BachelezH CribierB JolyP JullienD Oral cyclosporin in psoriasis: A systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis J Eur Acad Dermatol Venereol 2011 25 19 27 10.1111/j.1468-3083.2011.03992.x21388455 Search in Google Scholar

[41] Bardazzi F, Odorici G, Magnano M, Patrizi A, Tengattini V. Cyclosporine in clinical practice: A retrospective study comparing fixed dose and body weight-based dose regimens in psoriatic patients. G Ital Dermatol Venereol. 2018; 155: 146–149. BardazziF OdoriciG MagnanoM PatriziA TengattiniV Cyclosporine in clinical practice: A retrospective study comparing fixed dose and body weight-based dose regimens in psoriatic patients G Ital Dermatol Venereol 2018 155 146 149 10.23736/S0392-0488.18.05651-129368846 Search in Google Scholar

[42] Thaçi D, Bräutigam M, Kaufmann R, Weidinger G, Paul C, Christophers E. Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study. Dermatology. 2002; 205: 383–388. ThaçiD BräutigamM KaufmannR WeidingerG PaulC ChristophersE Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study Dermatology 2002 205 383 388 10.1159/00006642512444336 Search in Google Scholar

[43] Gisondi P, Del Giglio M, Di Francesco V, Zamboni M, Girolomoni G. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: A randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr. 2008; 88: 1242–1247. GisondiP Del GiglioM Di FrancescoV ZamboniM GirolomoniG Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: A randomized, controlled, investigator-blinded clinical trial Am J Clin Nutr 2008 88 1242 1247 Search in Google Scholar

[44] Corbetta S, Angioni R, Cattaneo A, Becke-Peccoz P, Spada A. Effects of retinoid therapy on insulin sensitivity, lipid profile and circulating adipocytokines. Eur J Endocrinol. 2006; 154: 83–86. CorbettaS AngioniR CattaneoA Becke-PeccozP SpadaA Effects of retinoid therapy on insulin sensitivity, lipid profile and circulating adipocytokines Eur J Endocrinol 2006 154 83 86 10.1530/eje.1.0205716381995 Search in Google Scholar

[45] Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol. 2008; 58: 443–446. ClarkL LebwohlM The effect of weight on the efficacy of biologic therapy in patients with psoriasis J Am Acad Dermatol 2008 58 443 446 10.1016/j.jaad.2007.11.01118083274 Search in Google Scholar

[46] Navarini AA, Poulin Y, Menter A, Gu Y, Teixeira HD. Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasis. J Drugs Dermatol. 2014; 13: 554–562. NavariniAA PoulinY MenterA GuY TeixeiraHD Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasis J Drugs Dermatol 2014 13 554 562 Search in Google Scholar

[47] Di Lernia V, Tasin L, Pellicano R, Zumiani G, Albertini G. Impact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasis. J Dermatolog Treat. 2012; 23: 404–409. Di LerniaV TasinL PellicanoR ZumianiG AlbertiniG Impact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasis J Dermatolog Treat 2012 23 404 409 10.3109/09546634.2011.59348921781016 Search in Google Scholar

[48] Saraceno R, Schipani C, Mazzotta A, Esposito M, Di Renzo L, De Lorenzo A, Chimenti S. Effect of anti-tumor necrosis factor-α therapies on body mass index in patients with psoriasis. Pharmacol Res. 2008; 57: 290–295. SaracenoR SchipaniC MazzottaA EspositoM Di RenzoL De LorenzoA ChimentiS Effect of anti-tumor necrosis factor-α therapies on body mass index in patients with psoriasis Pharmacol Res 2008 57 290 295 10.1016/j.phrs.2008.02.00618400510 Search in Google Scholar

[49] Dalamaga M, Papadavid E. Can we better strategize our choice of pharmacotherapy for patients with co-morbid psoriasis and obesity? Expert Opin Pharmacother. 2019; 20: 1303–1308. DalamagaM PapadavidE Can we better strategize our choice of pharmacotherapy for patients with co-morbid psoriasis and obesity? Expert Opin Pharmacother 2019 20 1303 1308 10.1080/14656566.2019.160329431002541 Search in Google Scholar

[50] Gisondi P, Girolomoni G. Impact of TNF-α antagonists on the quality of life in selected skin diseases. G Ital Dermatologia Venereol. 2013; 148: 243–248. GisondiP GirolomoniG Impact of TNF-α antagonists on the quality of life in selected skin diseases G Ital Dermatologia Venereol 2013 148 243 248 Search in Google Scholar

[51] Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CEM, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, et al. Secukinumab in plaque psoriasis: Results of two phase 3 trials. N Engl J Med. 2014; 371: 326–338. LangleyRG ElewskiBE LebwohlM ReichK GriffithsCEM PappK PuigL NakagawaH SpelmanL SigurgeirssonB Secukinumab in plaque psoriasis: Results of two phase 3 trials N Engl J Med 2014 371 326 338 10.1056/NEJMoa131425825007392 Search in Google Scholar

[52] Hegazy S, Konstantinou MP, Bulai Livideanu C, Tauber M, Paul C. Efficacy of ixekizumab in patients with resistance or incomplete response to secukinumab. J Eur Acad Dermatol Venereol. 2019; 33: e338–e341. HegazyS KonstantinouMP Bulai LivideanuC TauberM PaulC Efficacy of ixekizumab in patients with resistance or incomplete response to secukinumab J Eur Acad Dermatol Venereol 2019 33 e338 e341 10.1111/jdv.1563031001858 Search in Google Scholar

[53] Magdaleno-Tapial J, Carmena-Ramón R, Valenzuela-Oñate C, Ortiz-Salvador JM, Sabater-Abad J, Hernandez-Bel P, Gimeno-Carpio E, Sanchez-Carazo JL, Perez-Ferriols A. Efficacy and safety of ixekizumab in a real-life practice: A retrospective bicentric study. Actas Dermosifiliogr. 2019; 110: 585–589. Magdaleno-TapialJ Carmena-RamónR Valenzuela-OñateC Ortiz-SalvadorJM Sabater-AbadJ Hernandez-BelP Gimeno-CarpioE Sanchez-CarazoJL Perez-FerriolsA Efficacy and safety of ixekizumab in a real-life practice: A retrospective bicentric study Actas Dermosifiliogr 2019 110 585 589 10.1016/j.adengl.2019.06.004 Search in Google Scholar

[54] Lebwohl MG, Leonardi CL, Mehta NN, Gottlieb AB, Mendelsohn AM, Parno J, Rozzo SJ, Menter A. Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2). J Am Acad Dermatol. 2020; 82: 519–522. LebwohlMG LeonardiCL MehtaNN GottliebAB MendelsohnAM ParnoJ RozzoSJ MenterA Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2) J Am Acad Dermatol 2020 82 519 522 10.1016/j.jaad.2019.09.04231563641 Search in Google Scholar

[55] Ruiz-Villaverde R, Ayén-Rodriguez A, Llamas-Molina JM, Ruiz-Carrascosa JC. Risankizumab as a promising therapeutic approach in obese patients. Dermatol Ther. 2020; 33: e13323. Ruiz-VillaverdeR Ayén-RodriguezA Llamas-MolinaJM Ruiz-CarrascosaJC Risankizumab as a promising therapeutic approach in obese patients Dermatol Ther 2020 33 e13323 10.1111/dth.1332332196833 Search in Google Scholar

[56] Gordon KB, Blauvelt A, Foley P, Song M, Wasfi Y, Randazzo B, Shen YK, You Y, Griffiths CEM. Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: A pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol. 2018; 178: 132–139. GordonKB BlauveltA FoleyP SongM WasfiY RandazzoB ShenYK YouY GriffithsCEM Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: A pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies Br J Dermatol 2018 178 132 139 10.1111/bjd.1600828940259 Search in Google Scholar

[57] Torres T, Puig L. Apremilast: A novel oral treatment for psoriasis and psoriatic arthritis. Am J Clin. 2018; 19: 23–32. TorresT PuigL Apremilast: A novel oral treatment for psoriasis and psoriatic arthritis Am J Clin 2018 19 23 32 10.1007/s40257-017-0302-028597182 Search in Google Scholar

[58] Gisondi P, Girolomoni G. Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis. Drug Des Devel Ther. 2016; 10: 1763–1770. GisondiP GirolomoniG Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis Drug Des Devel Ther 2016 10 1763 1770 10.2147/DDDT.S108115488705327307707 Search in Google Scholar

[59] Charles-Schoeman C, Fleischmann R, Davignon J, Schwartz H, Turner SM, Beysen C, Milad M, Hellerstein MK, Luo Z, Kaplan IV, et al. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol. 2015; 67: 616–625. Charles-SchoemanC FleischmannR DavignonJ SchwartzH TurnerSM BeysenC MiladM HellersteinMK LuoZ KaplanIV Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib Arthritis Rheumatol 2015 67 616 625 10.1002/art.38974502406525470338 Search in Google Scholar

[60] Galluzzo M, D’Adamio S, Servoli S, Bianchi L, Chimenti S, Talamonti M. Tofacitinib for the treatment of psoriasis. Expert Opin Pharmacother. 2016; 17: 1421–1433. GalluzzoM D’AdamioS ServoliS BianchiL ChimentiS TalamontiM Tofacitinib for the treatment of psoriasis Expert Opin Pharmacother 2016 17 1421 1433 10.1080/14656566.2016.119581227267933 Search in Google Scholar

[61] Balak DMW. Fumaric acid esters in the management of psoriasis. Psoriasis Targets Ther. 2015; 5: 9–23. BalakDMW Fumaric acid esters in the management of psoriasis Psoriasis Targets Ther 2015 5 9 23 10.2147/PTT.S51490568311629387578 Search in Google Scholar

[62] Boehncke S, Fichtlscherer S, Salgo R, Garbaraviciene J, Beschmann H, Diehl S, Hardt K, Thaçi D, Boehncke WH. Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: Results of a prospective longitudinal pilot trial. Arch Dermatol Res. 2011; 303: 381–388. BoehnckeS FichtlschererS SalgoR GarbaravicieneJ BeschmannH DiehlS HardtK ThaçiD BoehnckeWH Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: Results of a prospective longitudinal pilot trial Arch Dermatol Res 2011 303 381 388 10.1007/s00403-010-1108-621170539 Search in Google Scholar

[63] Kim JY, Lee WJ, Lee SJ, Kim DW, Kim TH, Jun JB, Kim MB, Kim BS. An investigation on the use of complementary and alternative medicine for psoriasis. Korean J Dermatol. 2010; 48: 494–502. KimJY LeeWJ LeeSJ KimDW KimTH JunJB KimMB KimBS An investigation on the use of complementary and alternative medicine for psoriasis Korean J Dermatol 2010 48 494 502 Search in Google Scholar

[64] Johnson JA, Ma C, Kanada KN, Armstrong AW. Diet and nutrition in psoriasis: Analysis of the National Health and Nutrition Examination Survey (NHANES) in the United States. J Eur Acad Dermatol Venereol. 2014; 28: 327–332. JohnsonJA MaC KanadaKN ArmstrongAW Diet and nutrition in psoriasis: Analysis of the National Health and Nutrition Examination Survey (NHANES) in the United States J Eur Acad Dermatol Venereol 2014 28 327 332 10.1111/jdv.1210523432373 Search in Google Scholar

[65] Barrea L, Macchia PE, Tarantino G, Di Somma C, Pane E, Balato N, Napolitano M, Colao A, Savastano S. Nutrition: A key environmental dietary factor in clinical severity and cardio-metabolic risk in psoriatic male patients evaluated by 7-day food-frequency questionnaire. J Transl Med. 2015; 13: 303. BarreaL MacchiaPE TarantinoG Di SommaC PaneE BalatoN NapolitanoM ColaoA SavastanoS Nutrition: A key environmental dietary factor in clinical severity and cardio-metabolic risk in psoriatic male patients evaluated by 7-day food-frequency questionnaire J Transl Med 2015 13 303 10.1186/s12967-015-0658-y457106226376719 Search in Google Scholar

[66] Afifi L, Danesh MJ, Lee KM, Beroukhim K, Farahnik B, Ahn RS, Yan D, Singh RK, Nakamura M, Koo J, et al. Dietary behaviors in psoriasis: Patient-reported outcomes from a U.S. National Survey. Dermatol Ther. 2017; 7: 227–242. AfifiL DaneshMJ LeeKM BeroukhimK FarahnikB AhnRS YanD SinghRK NakamuraM KooJ Dietary behaviors in psoriasis: Patient-reported outcomes from a U.S. National Survey Dermatol Ther 2017 7 227 242 10.1007/s13555-017-0183-4545392528526915 Search in Google Scholar

[67] Solis MY, de Melo NS, Macedo MEM, Prata Carneiro F, Sabbag CY, Lancha AH Jr, Frangella VS. Nutritional status and food intake of patients with systemic psoriasis and psoriatic arthritis associated. Einstein. 2012; 10: 44–52. SolisMY de MeloNS MacedoMEM Prata CarneiroF SabbagCY LanchaAHJr FrangellaVS Nutritional status and food intake of patients with systemic psoriasis and psoriatic arthritis associated Einstein 2012 10 44 52 10.1590/S1679-45082012000100010 Search in Google Scholar

[68] Altunay I, Demirci GT, Ates B, Kucukunal A, Aydın C, Karamustafalıoglu O, Altuntas Y. Do eating disorders accompany metabolic syndrome in psoriasis patients? Results of a preliminary study. Clin Cosmet Investig Dermatol. 2011; 4: 139. AltunayI DemirciGT AtesB KucukunalA AydınC KaramustafalıogluO AltuntasY Do eating disorders accompany metabolic syndrome in psoriasis patients? Results of a preliminary study Clin Cosmet Investig Dermatol 2011 4 139 10.2147/CCID.S24165317301521931499 Search in Google Scholar

[69] Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: A population-based cohort study. Arch Dermatol. 2010; 146: 891–895. KurdSK TroxelAB Crits-ChristophP GelfandJM The risk of depression, anxiety, and suicidality in patients with psoriasis: A population-based cohort study Arch Dermatol 2010 146 891 895 Search in Google Scholar

[70] Simopoulos AP. An increase in the omega-6/omega-3 fatty acid ratio increases the risk for obesity. Nutrients. 2016; 8: 128. SimopoulosAP An increase in the omega-6/omega-3 fatty acid ratio increases the risk for obesity Nutrients 2016 8 128 10.3390/nu8030128480885826950145 Search in Google Scholar

[71] Upala S, Yong WC, Theparee T, Sanguankeo A. Effect of omega-3 fatty acids on disease severity in patients with psoriasis: A systematic review. Int J Rheum Dis. 2017; 20: 442–450. UpalaS YongWC ThepareeT SanguankeoA Effect of omega-3 fatty acids on disease severity in patients with psoriasis: A systematic review Int J Rheum Dis 2017 20 442 450 10.1111/1756-185X.1305128261950 Search in Google Scholar

[72] Madden SK, Flanagan KL, Jones G. How lifestyle factors and their associated pathogenetic mechanisms impact psoriasis. Clin Nutr, 2020; 39: 1026–1040. MaddenSK FlanaganKL JonesG How lifestyle factors and their associated pathogenetic mechanisms impact psoriasis Clin Nutr 2020 39 1026 1040 10.1016/j.clnu.2019.05.00631155371 Search in Google Scholar

[73] Honda T, Kabashima K. Current understanding of the role of dietary lipids in the pathophysiology of psoriasis. J Dermatol Sci. 2019; 94: 314–320. HondaT KabashimaK Current understanding of the role of dietary lipids in the pathophysiology of psoriasis J Dermatol Sci 2019 94 314 320 10.1016/j.jdermsci.2019.05.00331133503 Search in Google Scholar

[74] Barrea L, Balato N, Di Somma C, Macchia PE, Napolitano M, Savanelli MC, Esposito K, Colao A, Savastano S. Nutrition and psoriasis: Is there any association between the severity of the disease and adherence to the Mediterranean diet? J Transl Med. 2015; 13: 18. BarreaL BalatoN Di SommaC MacchiaPE NapolitanoM SavanelliMC EspositoK ColaoA SavastanoS Nutrition and psoriasis: Is there any association between the severity of the disease and adherence to the Mediterranean diet? J Transl Med 2015 13 18 10.1186/s12967-014-0372-1431665425622660 Search in Google Scholar

[75] Dennis EA, Norris PC. Eicosanoid storm in infection and inflammation. Nat Rev Immunol. 2015; 15: 511–523. DennisEA NorrisPC Eicosanoid storm in infection and inflammation Nat Rev Immunol 2015 15 511 523 10.1038/nri3859460686326139350 Search in Google Scholar

[76] Calder PC. Fatty acids and inflammation: The cutting edge between food and pharma. Eur J Pharmacol. 2011; 668: S50–S58. CalderPC Fatty acids and inflammation: The cutting edge between food and pharma Eur J Pharmacol 2011 668 S50 S58 10.1016/j.ejphar.2011.05.08521816146 Search in Google Scholar

[77] Fischer R, Konkel A, Mehling H, Blossey K, Gapelyuk A, Wessel N, von Schacky C, Dechend R, Muller DN, Rothe M, et al. Dietary omega-3 fatty acids modulate the eicosanoid profile in man primarily via the CYP-epoxygenase pathway. J Lipid Res. 2014; 55: 1150–1164. FischerR KonkelA MehlingH BlosseyK GapelyukA WesselN von SchackyC DechendR MullerDN RotheM Dietary omega-3 fatty acids modulate the eicosanoid profile in man primarily via the CYP-epoxygenase pathway J Lipid Res 2014 55 1150 1164 10.1194/jlr.M047357403194624634501 Search in Google Scholar

[78] Calder PC, Albers R, Antoine JM, Blum S, Bourdet-Sicard R, Ferns GA, Folkerts G, Friedmann PS, Frost GS, Guarner F, et al. Inflammatory disease processes and interactions with nutrition. Br J Nutr. 2009; 101: S1–S45. CalderPC AlbersR AntoineJM BlumS Bourdet-SicardR FernsGA FolkertsG FriedmannPS FrostGS GuarnerF Inflammatory disease processes and interactions with nutrition Br J Nutr 2009 101 S1 S45 10.1017/S000711450937786719586558 Search in Google Scholar

[79] Michaëlsson G, Gerdén B, Ottosson M, Parra A, Sjöberg O, Hjelmquist G, Lööf L. Patients with psoriasis often have increased serum levels of IgA antibodies to gliadin. Br J Dermatol. 1993; 129: 667–673. MichaëlssonG GerdénB OttossonM ParraA SjöbergO HjelmquistG LööfL Patients with psoriasis often have increased serum levels of IgA antibodies to gliadin Br J Dermatol 1993 129 667 673 10.1111/j.1365-2133.1993.tb03329.x8286249 Search in Google Scholar

[80] Infantino M, Manfredi M, Meacci F, Grossi V, Severino M, Benucci M, Bellio E, Bellio V, Nucci A, Zolfanelli F, et al. Diagnostic accuracy of anti-gliadin antibodies in Non-Celiac Gluten Sensitivity (NCGS) patients: A dual statistical approach. Clin Chim Acta, 2015; 451: 135–141. InfantinoM ManfrediM MeacciF GrossiV SeverinoM BenucciM BellioE BellioV NucciA ZolfanelliF Diagnostic accuracy of anti-gliadin antibodies in Non-Celiac Gluten Sensitivity (NCGS) patients: A dual statistical approach Clin Chim Acta 2015 451 135 141 10.1016/j.cca.2015.09.01726404177 Search in Google Scholar

[81] Acharya P, Mathur M. Association between psoriasis and celiac disease: A systematic review and meta-analysis. J Am Acad Dermatol. 2020; 82: 1376–1385. AcharyaP MathurM Association between psoriasis and celiac disease: A systematic review and meta-analysis J Am Acad Dermatol 2020 82 1376 1385 10.1016/j.jaad.2019.11.03931809817 Search in Google Scholar

[82] Lin L, Zhang J. Role of intestinal microbiota and metabolites on gut homeostasis and human diseases. BMC Immunol. 2017; 18: 1–25. LinL ZhangJ Role of intestinal microbiota and metabolites on gut homeostasis and human diseases BMC Immunol 2017 18 1 25 10.1186/s12865-016-0187-3521968928061847 Search in Google Scholar

[83] Drucker AM, Qureshi AA, Thompson JM, Li T, Cho E. Gluten intake and risk of psoriasis, psoriatic arthritis, and atopic dermatitis among United States women. J Am Acad Dermatol. 2020; 82: 661–665. DruckerAM QureshiAA ThompsonJM LiT ChoE Gluten intake and risk of psoriasis, psoriatic arthritis, and atopic dermatitis among United States women J Am Acad Dermatol 2020 82 661 665 10.1016/j.jaad.2019.08.007700784831404570 Search in Google Scholar

[84] Ford AR, Siegel M, Bagel J, Cordoro KM, Garg A, Gottlieb A, Green LJ, Gudjonsson JE, Koo J, Lebwohl M, et al.: Dietary recommendations for adults with psoriasis or psoriatic arthritis from the Medical Board of the National Psoriasis Foundation: a systematic review. JAMA Dermatology. 2018; 154: 934–950. FordAR SiegelM BagelJ CordoroKM GargA GottliebA GreenLJ GudjonssonJE KooJ LebwohlM Dietary recommendations for adults with psoriasis or psoriatic arthritis from the Medical Board of the National Psoriasis Foundation: a systematic review JAMA Dermatology 2018 154 934 950 10.1001/jamadermatol.2018.141229926091 Search in Google Scholar

[85] Szepietowski J, Pietrzak A, Michalak-Stoma A, Chodorowska G. Lipid disturbances in psoriasis: An update. Mediators Inflamm. 2010; 2010: 535612. SzepietowskiJ PietrzakA Michalak-StomaA ChodorowskaG Lipid disturbances in psoriasis: An update Mediators Inflamm 2010 2010 535612 Search in Google Scholar

[86] Wakkee M, Thio HB, Prens EP, Sijbrands EJG, Neumann HAM. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis. 2007; 190: 1–9. WakkeeM ThioHB PrensEP SijbrandsEJG NeumannHAM Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients Atherosclerosis 2007 190 1 9 10.1016/j.atherosclerosis.2006.07.01116942772 Search in Google Scholar

[87] NazIroǧlu M, YIldIz K, Tamtürk B, Erturan I, Flores-Arce M. Selenium and psoriasis. Biol Trace Elem Res. 2012; 150: 3–9. NazIroǧluM YIldIzK TamtürkB ErturanI Flores-ArceM Selenium and psoriasis Biol Trace Elem Res 2012 150 3 9 10.1007/s12011-012-9479-522821504 Search in Google Scholar

[88] Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta, 2001; 303: 33–39. Rocha-PereiraP Santos-SilvaA RebeloI FigueiredoA QuintanilhaA TeixeiraF Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease Clin Chim Acta 2001 303 33 39 10.1016/S0009-8981(00)00358-2 Search in Google Scholar

[89] Kökçam I, Naziroǧlu M. Antioxidants and lipid peroxidation status in the blood of patients with psoriasis. Clin Chim Acta, 1999; 289: 23–31. KökçamI NaziroǧluM Antioxidants and lipid peroxidation status in the blood of patients with psoriasis Clin Chim Acta 1999 289 23 31 10.1016/S0009-8981(99)00150-3 Search in Google Scholar

[90] Serwin AB, Wasowicz W, Chodynicka B. Selenium supplementation, soluble tumor necrosis factor-α receptor type 1, and C-reactive protein during psoriasis therapy with narrowband ultraviolet B. Nutrition. 2006; 22: 860–864. SerwinAB WasowiczW ChodynickaB Selenium supplementation, soluble tumor necrosis factor-α receptor type 1, and C-reactive protein during psoriasis therapy with narrowband ultraviolet B Nutrition 2006 22 860 864 10.1016/j.nut.2006.05.01116829029 Search in Google Scholar

[91] Serwin AB, Wasowicz W, Gromadzinska J, Chodynicka B. Selenium status in psoriasis and its relations to the duration and severity of the disease. Nutrition. 2003; 19: 301–304. SerwinAB WasowiczW GromadzinskaJ ChodynickaB Selenium status in psoriasis and its relations to the duration and severity of the disease Nutrition 2003 19 301 304 10.1016/S0899-9007(02)01081-X Search in Google Scholar

[92] Kharaeva Z, Gostova E, De Luca C, Raskovic D, Korkina L. Clinical and biochemical effects of coenzyme Q10, vitamin E, and selenium supplementation to psoriasis patients. Nutrition. 2009; 25: 295–302. KharaevaZ GostovaE De LucaC RaskovicD KorkinaL Clinical and biochemical effects of coenzyme Q10, vitamin E, and selenium supplementation to psoriasis patients Nutrition 2009 25 295 302 10.1016/j.nut.2008.08.01519041224 Search in Google Scholar

[93] Barrea L, Savanelli MC, Di Somma C, Napolitano M, Megna M, Colao A, Savastano S. Vitamin D and its role in psoriasis: An overview of the dermatologist and nutritionist. Rev Endocr Metab Disord. 2017; 18: 195–205. BarreaL SavanelliMC Di SommaC NapolitanoM MegnaM ColaoA SavastanoS Vitamin D and its role in psoriasis: An overview of the dermatologist and nutritionist Rev Endocr Metab Disord 2017 18 195 205 10.1007/s11154-017-9411-6548690928176237 Search in Google Scholar

[94] Lee YH, Song GG. Association between circulating 25-hydroxyvitamin D levels and psoriasis, and correlation with disease severity: A meta-analysis. Clin Exp Dermatol. 2018; 43: 529–535. LeeYH SongGG Association between circulating 25-hydroxyvitamin D levels and psoriasis, and correlation with disease severity: A meta-analysis Clin Exp Dermatol 2018 43 529 535 10.1111/ced.1338129341195 Search in Google Scholar

[95] Merola JF, Han J, Li T, Qureshi AA. No association between vitamin D intake and incident psoriasis among US women. Arch Dermatol Res. 2014; 306: 305–307. MerolaJF HanJ LiT QureshiAA No association between vitamin D intake and incident psoriasis among US women Arch Dermatol Res 2014 306 305 307 10.1007/s00403-013-1426-624232773 Search in Google Scholar

[96] Ricketts JR, Rothe MJ, Grant-Kels JM. Nutrition and psoriasis. Clin Dermatol. 2010; 28: 615–626. RickettsJR RotheMJ Grant-KelsJM Nutrition and psoriasis Clin Dermatol 2010 28 615 626 10.1016/j.clindermatol.2010.03.02721034986 Search in Google Scholar

[97] Zuccotti E, Oliveri M, Girometta C, Ratto D, Di Iorio C, Occhinegro A, Rossi P. Nutritional strategies for psoriasis: Current scientific evidence in clinical trials. Eur Rev Med Pharmacol Sci. 2018; 22: 8537–8551. ZuccottiE OliveriM GiromettaC RattoD Di IorioC OcchinegroA RossiP Nutritional strategies for psoriasis: Current scientific evidence in clinical trials Eur Rev Med Pharmacol Sci 2018 22 8537 8551 Search in Google Scholar

[98] Owczarczyk-Saczonek A, Placek W. Is the diet important for psoriasis? Przegl Dermatol. 2014; 101: 319–326. Owczarczyk-SaczonekA PlacekW Is the diet important for psoriasis? Przegl Dermatol 2014 101 319 326 10.5114/dr.2014.45127 Search in Google Scholar

[99] Wolters M. Diet and psoriasis: Experimental data and clinical evidence. Br J Dermatol. 2005; 153: 706–714. WoltersM Diet and psoriasis: Experimental data and clinical evidence Br J Dermatol 2005 153 706 714 10.1111/j.1365-2133.2005.06781.x16181450 Search in Google Scholar

[100] Hsieh EA, Chai CM, De Lumen BO, Neese RA, Hellerstein MK. Dynamics of keratinocytes in vivo using ²H₂O labeling: A sensitive marker of epidermal proliferation state. J Invest Dermatol. 2004; 123: 530–536. HsiehEA ChaiCM De LumenBO NeeseRA HellersteinMK Dynamics of keratinocytes in vivo using ²H₂O labeling: A sensitive marker of epidermal proliferation state J Invest Dermatol 2004 123 530 536 10.1111/j.0022-202X.2004.23303.x15304093 Search in Google Scholar

[101] Andersen V, Holmskov U, Bek Sørensen S, Jawhara M, Andersen KW, Bygum A, Hvid L, Grauslund J, Wied J, Glerup H, et al. A proposal for a study on treatment selection and lifestyle recommendations in chronic inflammatory diseases: A Danish multidisciplinary collaboration on prognostic factors and personalised medicine. Nutrients. 2017; 9: 499. AndersenV HolmskovU Bek SørensenS JawharaM AndersenKW BygumA HvidL GrauslundJ WiedJ GlerupH A proposal for a study on treatment selection and lifestyle recommendations in chronic inflammatory diseases: A Danish multidisciplinary collaboration on prognostic factors and personalised medicine Nutrients 2017 9 499 10.3390/nu9050499545222928505128 Search in Google Scholar

[102] Al-Mutairi N, Nour T. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: A randomized controlled prospective trial. Expert Opin Biol Ther. 2014; 14: 749–756. Al-MutairiN NourT The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: A randomized controlled prospective trial Expert Opin Biol Ther 2014 14 749 756 10.1517/14712598.2014.90054124661040 Search in Google Scholar

[103] Jensen P, Christensen R, Zachariae C, Geiker NR, Schaadt BK, Stender S, Hansen PR, Astrup A, Skov L. Long-term effects of weight reduction on the severity of psoriasis in a cohort derived from a randomized trial: A prospective observational follow-up study. Am J Clin Nutr. 2016; 104: 259–265. JensenP ChristensenR ZachariaeC GeikerNR SchaadtBK StenderS HansenPR AstrupA SkovL Long-term effects of weight reduction on the severity of psoriasis in a cohort derived from a randomized trial: A prospective observational follow-up study Am J Clin Nutr 2016 104 259 265 10.3945/ajcn.115.12584927334236 Search in Google Scholar

[104] Ručević I, Perl A, Barišić-Druško V, Adam-Perl M. The role of the low energy diet in psoriasis vulgaris treatment. Coll Antropol. 2003; 27: 41–48. RučevićI PerlA Barišić-DruškoV Adam-PerlM The role of the low energy diet in psoriasis vulgaris treatment Coll Antropol 2003 27 41 48 Search in Google Scholar

[105] Castaldo G, Rastrelli L, Galdo G, Molettieri P, Rotondi Aufiero F, Cereda E. Aggressive weight-loss program with a ketogenic induction phase for the treatment of chronic plaque psoriasis: A proof-of-concept, single-arm, open-label clinical trial. Nutrition. 2020; 74: 110757. CastaldoG RastrelliL GaldoG MolettieriP Rotondi AufieroF CeredaE Aggressive weight-loss program with a ketogenic induction phase for the treatment of chronic plaque psoriasis: A proof-of-concept, single-arm, open-label clinical trial Nutrition 2020 74 110757 10.1016/j.nut.2020.11075732222582 Search in Google Scholar

[106] Caso F, Navarini L, Carubbi F, Diamanti AP, Chimenti MS, Tasso M, Currado D, Ruscitti P, Ciccozzi M, Annarumma A, et al.: Mediterranean diet and psoriatic arthritis activity: A multicenter cross-sectional study. Rheumatol Int. 2020; 40: 951–958. CasoF NavariniL CarubbiF DiamantiAP ChimentiMS TassoM CurradoD RuscittiP CiccozziM AnnarummaA Mediterranean diet and psoriatic arthritis activity: A multicenter cross-sectional study Rheumatol Int 2020 40 951 958 10.1007/s00296-019-04458-731605152 Search in Google Scholar

[107] Phan C, Touvier M, Kesse-Guyot E. Adjibade M, Hercberg S, Wolkenstein P, Chosidow O, Ezzedine K, Sbidian E. Association between Mediterranean anti-inflammatory dietary profile and severity of psoriasis: Results from the NutriNet-Santé cohort. JAMA Dermatology. 2018; 154: 1017–1024. PhanC TouvierM Kesse-GuyotE AdjibadeM HercbergS WolkensteinP ChosidowO EzzedineK SbidianE Association between Mediterranean anti-inflammatory dietary profile and severity of psoriasis: Results from the NutriNet-Santé cohort JAMA Dermatology 2018 154 1017 1024 10.1001/jamadermatol.2018.2127614302930046840 Search in Google Scholar

[108] Molina-Leyva A, Cuenca-Barrales C, Vega-Castillo JJ, Ruiz-Carrascosa JC, Ruiz-Villaverde R. Adherence to Mediterranean diet in Spanish patients with psoriasis: Cardiovascular benefits? Dermatol Ther. 2019; 32: e12810. Molina-LeyvaA Cuenca-BarralesC Vega-CastilloJJ Ruiz-CarrascosaJC Ruiz-VillaverdeR Adherence to Mediterranean diet in Spanish patients with psoriasis: Cardiovascular benefits? Dermatol Ther 2019 32 e12810 10.1111/dth.1281030632241 Search in Google Scholar

[109] Lithell H, Bruce A, Gustafsson IB, Höglund NJ, Karlström B, Ljunghall K, Sjölin K, Venge P, Werner I, Vessby B. A fasting and vegetarian diet treatment trial on chronic inflammatory disorders. Acta Derm Venereol. 1983; 63: 397–403. LithellH BruceA GustafssonIB HöglundNJ KarlströmB LjunghallK SjölinK VengeP WernerI VessbyB A fasting and vegetarian diet treatment trial on chronic inflammatory disorders Acta Derm Venereol 1983 63 397 403 Search in Google Scholar